专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08529901B2 Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label 有权
标题翻译：结合肿瘤抗原的第一非标记单克隆抗体和用NIR荧光标记标记的非交叉反应性第二单克隆抗体的组成
公开(公告)号：US08529901B2
公开(公告)日：2013-09-10
申请号：US12599713
申请日：2008-06-04
申请人： Max Hasmann , Helmut Lenz , Werner Scheuer
发明人： Max Hasmann , Helmut Lenz , Werner Scheuer
IPC分类号： A61K39/395
CPC分类号： A61K49/0058 , A61K39/39558 , A61K49/0032
摘要： This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.
摘要翻译：本发明涉及结合肿瘤抗原的非标记单克隆抗体的组合物和用NIR荧光标记物标记的第二单克隆抗体，其结合相同的肿瘤抗原，其中第一抗体和第二抗体不显示交叉反应性。该组合物可用于治疗与这种肿瘤抗原的过表达相关的实体瘤患者。本发明还涉及所述第一和第二抗体的共同给药，以获得在用所述组合物治疗所述患者期间获得这种肿瘤的NIR荧光图像或患有此类肿瘤的患者的方法。

2. 发明申请

US20110027190A1 COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL 有权
标题翻译：第一个非标记的单克隆抗体与肿瘤抗原结合的组合物和标记有近红色荧光标记的非交叉反应性第二单克隆抗体
公开(公告)号：US20110027190A1
公开(公告)日：2011-02-03
申请号：US12599713
申请日：2008-06-04
申请人： Max Hasmann , Helmut Lenz , Werner Scheuer
发明人： Max Hasmann , Helmut Lenz , Werner Scheuer
IPC分类号： A61K49/00 , A61P35/00 , A61K39/395
CPC分类号： A61K49/0058 , A61K39/39558 , A61K49/0032
摘要： This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.
摘要翻译：本发明涉及结合肿瘤抗原的非标记单克隆抗体的组合物和用NIR荧光标记标记的第二单克隆抗体，其结合相同的肿瘤抗原，其中第一抗体和第二抗体不表现出交叉反应性。该组合物可用于治疗与这种肿瘤抗原的过表达相关的实体瘤患者。本发明还涉及所述第一和第二抗体的共同给药，以获得在用所述组合物治疗所述患者期间获得这种肿瘤的NIR荧光图像或患有此类肿瘤的患者的方法。

3. 发明申请

US20110223159A1 TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY 审中-公开
标题翻译：肿瘤治疗与抗VEGF抗体
公开(公告)号：US20110223159A1
公开(公告)日：2011-09-15
申请号：US13111784
申请日：2011-05-19
申请人： Thomas Friess , Max Hasmann , Werner Scheuer
发明人： Thomas Friess , Max Hasmann , Werner Scheuer
IPC分类号： A61K39/395 , A61P35/00 , A61P35/04
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K2317/76 , C07K2317/92
摘要： The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.
摘要翻译：本发明提供了在用抗HER2抗体治疗期间或之后用抗VEGF抗体治疗患有复发性HER2阳性癌症的患者的方法。本发明还提供了包含抗VEGF抗体的试剂盒。

4. 发明申请

US20110064736A1 TUMOR THERAPY WITH AN ANTIBODY FOR VASCULAR ENDOTHELIAL GROWTH FACTOR AND AN ANTIBODY FOR HUMAN EPITHELIAL GROWTH FACTOR RECEPTOR TYPE 2 审中-公开
标题翻译：肿瘤治疗与血管内皮生长因子和人类上皮生长因子受体2型抗体的抗体
公开(公告)号：US20110064736A1
公开(公告)日：2011-03-17
申请号：US12947264
申请日：2010-11-16
申请人： Thomas Friess , Max Hasmann , Werner Scheuer
发明人： Thomas Friess , Max Hasmann , Werner Scheuer
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K39/3955 , A61K2039/507 , C07K16/22 , C07K16/3015 , C07K16/32 , C07K2317/24
摘要： The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
摘要翻译：本发明提供了一种治疗患有先前用抗VEGF抗体治疗失败的患者的乳腺癌疾病的方法，其包括向患者施用治疗有效量的抗HER2抗体，同时继续进行所述抗VEGF抗体治疗。本发明还提供相应的药物试剂盒和药物组合物。

5. 发明申请

US20080102069A1 TUMOR THERAPY WITH A COMBINATION OF ANTI-HER2 ANTIBODIES 审中-公开
标题翻译：肿瘤治疗与抗HER2抗体的组合
公开(公告)号：US20080102069A1
公开(公告)日：2008-05-01
申请号：US11854584
申请日：2007-09-13
申请人： Thomas Friess , Max Hasmann , Werner Scheuer
发明人： Thomas Friess , Max Hasmann , Werner Scheuer
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/32 , A61K2039/507 , C07K2317/24
摘要： The present invention provides a method for treating HER2 positive cancer or metastasis of HER2 positive cancer in a patient, who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab or to successive monotherapies with trastuzumab and pertuzumab, comprising co-administering to said patient a therapeutically-effective amount of trastuzumab and pertuzumab simultaneously or sequentially. The invention also provides A kit which comprises trastuzumab and pertuzumab and a package insert instructing the user to co-administer trastuzumab and pertuzumab to a patient suffering from HER2 positive cancer who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab.
摘要翻译：本发明提供了一种用于治疗HER2阳性癌症的HER2阳性癌症或转移的方法，所述方法不对曲妥珠单抗单药治疗或使用妥他珠单抗或与曲妥单抗和依托单抗连续单药治疗无反应，包括共同施用同时或顺序地向患者提供治疗有效量的曲妥单抗和依妥珠单抗。本发明还提供了一种试剂盒，其包含曲妥珠单抗和依妥珠单抗和包装说明书，其指示使用者将曲妥珠单抗和依托单抗联合给患有HER2阳性癌症的患者，其对曲妥珠单抗的单一疗法或使用妥珠单抗的单一疗法无反应。

6. 发明申请

US20100285010A1 TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY 审中-公开
标题翻译：肿瘤治疗与抗VEGF抗体
公开(公告)号：US20100285010A1
公开(公告)日：2010-11-11
申请号：US12784309
申请日：2010-05-20
申请人： Thomas Friess , Max Hasmann , Werner Scheuer
发明人： Thomas Friess , Max Hasmann , Werner Scheuer
IPC分类号： A61K39/395 , A61P35/00 , B65D85/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K2317/76 , C07K2317/92
摘要： The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.
摘要翻译：本发明提供了在用抗HER2抗体治疗期间或之后用抗VEGF抗体治疗患有复发性HER2阳性癌症的患者的方法。本发明还提供了包含抗VEGF抗体的试剂盒。

7. 发明授权

US09090700B2 Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 有权
标题翻译：用血管内皮生长因子抗体和2型人类上皮生长因子受体的抗体进行肿瘤治疗
公开(公告)号：US09090700B2
公开(公告)日：2015-07-28
申请号：US12947264
申请日：2010-11-16
申请人： Thomas Friess , Max Hasmann , Werner Scheuer
发明人： Thomas Friess , Max Hasmann , Werner Scheuer
IPC分类号： A61K39/395 , C07K16/32 , C07K16/22 , C07K16/30 , A61K39/00
CPC分类号： A61K39/39558 , A61K39/3955 , A61K2039/507 , C07K16/22 , C07K16/3015 , C07K16/32 , C07K2317/24
摘要： The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
摘要翻译：本发明提供了一种治疗患有先前用抗VEGF抗体治疗失败的患者的乳腺癌疾病的方法，其包括向患者施用治疗有效量的抗HER2抗体，同时继续进行所述抗VEGF抗体治疗。本发明还提供相应的药物试剂盒和药物组合物。

8. 发明申请

US20130183292A1 TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY 审中-公开
公开(公告)号：US20130183292A1
公开(公告)日：2013-07-18
申请号：US13585095
申请日：2012-08-14
申请人： Thomas Friess , Max Hasmann , Werner Scheuer
发明人： Thomas Friess , Max Hasmann , Werner Scheuer
IPC分类号： A61K39/395
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K2317/76 , C07K2317/92
摘要： The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.

9. 发明申请

US20080050385A1 TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY 审中-公开
标题翻译：肿瘤治疗与抗VEGF抗体
公开(公告)号：US20080050385A1
公开(公告)日：2008-02-28
申请号：US11840279
申请日：2007-08-17
申请人： Thomas Friess , Max Hasmann , Werner Scheuer
发明人： Thomas Friess , Max Hasmann , Werner Scheuer
IPC分类号： A61K39/395 , A61P35/00 , A61P35/04
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K2317/76 , C07K2317/92
摘要： The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.
摘要翻译：本发明提供了在用抗HER2抗体治疗期间或之后用抗VEGF抗体治疗患有复发性HER2阳性癌症的患者的方法。本发明还提供了包含抗VEGF抗体的试剂盒。

10. 发明申请

US20070224203A1 Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 审中-公开
标题翻译：用血管内皮生长因子抗体和2型人类上皮生长因子受体的抗体进行肿瘤治疗
公开(公告)号：US20070224203A1
公开(公告)日：2007-09-27
申请号：US11725777
申请日：2007-03-20
申请人： Thomas Friess , Max Hasmann , Werner Scheuer
发明人： Thomas Friess , Max Hasmann , Werner Scheuer
IPC分类号： A61K39/395
CPC分类号： A61K39/39558 , A61K39/3955 , A61K2039/507 , C07K16/22 , C07K16/3015 , C07K16/32 , C07K2317/24
摘要： The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
摘要翻译：本发明提供了一种治疗患有先前用抗VEGF抗体治疗失败的患者的乳腺癌疾病的方法，其包括向患者施用治疗有效量的抗HER2抗体，同时继续进行所述抗VEGF抗体治疗。本发明还提供相应的药物试剂盒和药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式